Targeted Therapy For AIDS-related Kaposi's Sarcoma by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open AccessOral presentation
Targeted Therapy For AIDS-related Kaposi's Sarcoma
Henry Koon*‡
Address: Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Email: Henry Koon* - hkoon@bidmc.harvard.edu
* Corresponding author    ‡Presenting author    
Angiogenesis plays a critical in the pathogenesis of
Kaposi's sarcoma. Platelet derived growth factor (PDGF),
vascular endothelial growth factor, fibroblast growth fac-
tor and matrix metalloproteinases (MMP) are among the
angiogenic pathways that have been implicated in the
development of Kaposi's sarcoma. The introduction of
specific therapies such as imatinib and Col-3 that target
the PDGF pathway and MMPs, respectively, provide a
mechanism to test the importance of these pathways in
Kaposi's sarcoma in vivo. In this session the rationale for
targeted therapy in Kaposi's sarcoma will be discussed.
The results from recent trials involving anti-angiogenic
agents and signal transduction inhibitors will be
reviewed. Additionally, trials of targeted therapies that are
underway or in development will be outlined.
from 2005 International Meeting of The Institute of Human Virology
Baltimore, USA, 29 August – 2 September 2005
Published: 8 December 2005
Retrovirology 2005, 2(Suppl 1):S45 doi:10.1186/1742-4690-2-S1-S45
<supplement> <title> <p>2005 International Meeting of The Institute of Human Virology</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. [link 'here' using 'a href' to: <url>http://www.biomedcentral.com/content/pdf/1742-4690-2-S1-full. df</url>]</not /supplement>
